Clinical trial

A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer

NCT01931943

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2013-04-01

PhasePHASE1

Study timeline

Study start (unknown)2013-04-01Date precision: month

Registry last updated2013-08-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Breast Cancerunresolved

Interventions

selatinib ditosilate tabletsDRUG

Sponsors & collaborators

Qilu Pharmaceutical Co., Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01931943 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.